Case Report: Bullous erythema multiforme induced by omalizumab - Takeaways - MDSpire

Case Study: Omalizumab-Induced Bullous Erythema Multiforme

By
Zenan Tang
Yan Zhao
July 17, 2026

Frontiers In Medicine

Share

1

Bullous erythema multiforme (BEM) is an acute immune-mediated mucocutaneous disease often triggered by medications.
2

Omalizumab, a monoclonal antibody for chronic spontaneous urticaria, can induce rare severe cutaneous reactions like BEM.
3

A 36-year-old woman developed BEM after her first omalizumab injection, presenting with widespread lesions and systemic symptoms.
4

Laboratory tests revealed elevated eosinophil count and IgE levels, while skin biopsy confirmed the diagnosis of omalizumab-induced BEM.
5

Treatment with high-dose glucocorticoids and JAK inhibitors was effective in controlling the patient's refractory BEM.

Original Source(s)

Frontiers In Medicine

Case Report: Bullous erythema multiforme induced by omalizumab

by Zenan Tang, Yan Zhao
July 17, 2026

Related Content

Frontiers In Medicine

The role and signal pathways of opsin 3 in the skin: from light perception to pathophysiological mechanisms

by Qian Zhang, Yanyan Feng
July 15, 2026

Conexiant

Mental Health May Impact Dermatologic Quality of Life

Poorer dermatology-related quality of life was associated with greater mental health issues, while habitual probiotic intake showed no measurable relationship with these outcomes.